Integrated sample preparation and real-time PCR assay for the quantitation of E. coli host cell DNA.
-
Highly sensitive quantitation using proven TaqMan® real-time qPCR technology (Figure 1)
-
Manual and automated sample preparation, optimized for quantitative recovery from complex sample matrices (Table 1)
-
Enables consistent performance across the expected range of DNA fragment sizes (Figure 2)
-
Integrated system from sample to results with sample preparation, master mix, TaqMan® primer/probe mix, and genomic DNA standard
To learn more, click here >>
|
|
|
|
|
The Society of Biology is the largest professional body for the biological sciences in the United Kingdom – representing over 11,500 individual life scientists and 90 member organisations. Membership of the Society will help you stay up to date with what is happening across the life sciences and provide you with additional recognition for your skills and experience. Members can become Chartered through the Society and we offer two professional awards: Chartered Biologist (CBiol) and Chartered Scientist (CSci). Which award is best for you depends on your particular job role, circumstances and personal self-identification as a biologist or a scientist.
Click here for more information about the benefits of membership >>
|
|
|
|
|
|
|
|
|
|
|
|
AstraZeneca have announced today that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012. A French national, 53 year old Pascal Soriot joins AstraZeneca from Roche AG where he has served as Chief Operating Officer of the company’s pharmaceuticals division since 2010.
Read full story >>
|
|
 |
|
|
|
|
|
|
|
Handheld Raman: Cut costs, improve efficiency & move toward 100% testing
 |
|
In this one hour instructional webinar we will discuss how handheld Raman reduces costs and improves efficiency, the move to mandatory 100% testing of incoming raw materials, and recent developments in handheld Raman technology:
-
The move to mandatory 100% testing of incoming raw materials
Ravi Kalyanaraman PhD, Principal Scientist, Bristol Myers Squibb
-
How handheld Raman improves efficiency
John Kauffman, Research Chemist at FDA
Find out more >>
|
|
|
|
Conferences, events & exhibitions:
Genomics Research Europe
4 - 5 September 2012 Frankfurt, Germany
ELRIG Drug Discovery 2012
5 - 6 September 2012 Manchester, UK
HUPO 11th Annual World Congress
9 - 12 September 2012 Boston, USA
Design Control for Medical Device Professionals
10 - 11 September 2012 Berlin, Germany
Design Validation, Verification, and Risk Analysis for Medical Device Professionals
12 - 13 September 2012 Berlin, Germany
Validation of Computer Systems
17 - 18 September 2012 Dublin, Ireland
The EU Clinical Trial Directive
17 - 18 September 2012 Dublin, Ireland
ADME, PK/TK, and Drug Metabolism in Drug Discovery and Development
17 - 19 September 2012 Dublin, Ireland
The Drug Development Process – From Discovery to Commercialisation
19 - 21 September 2012 Dublin, Ireland
11th Annual Biological Production Forum 2012
24 - 26 September 2012 Dusseldorf, Germany
MipTec 2012
24 - 27 September 2012 Basel, Switzerland
Lab-on-a-Chip World Congress
25 - 26 September 2012 San Diego, USA
|
|
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
